Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | 0 | uM | 9 | 625.00 | 320.09 | 564.00 | 843.25 | 0.6688 | 0.4998 | |
| BT-20 | Linsitinib | 1 | uM | 9 | 625.00 | 320.09 | 692.00 | 843.25 | 0.8206 | 0.7362 |
| BT-20 | Erlotinib | 0.31623 | uM | 9 | 625.00 | 320.09 | 809.00 | 843.25 | 0.9594 | 0.9415 |
| BT-20 | 0 | uM | 9 | 625.00 | 320.09 | 952.00 | 843.25 | 1.1290 | 1.1814 | |
| BT-20 | Linsitinib | 19.9526 | uM | 9 | 625.00 | 320.09 | 384.00 | 843.25 | 0.4554 | 0.1391 |
| BT-20 | Linsitinib | 0.0033113 | uM | 9 | 625.00 | 320.09 | 1160.00 | 843.25 | 1.3756 | 1.5127 |
| BT-20 | Erlotinib | 10 | uM | 9 | 625.00 | 320.09 | 534.00 | 843.25 | 0.6333 | 0.4423 |
| BT-20 | Erlotinib | 3.1623 | uM | 9 | 625.00 | 320.09 | 887.00 | 843.25 | 1.0519 | 1.0737 |
| BT-20 | 17-AAG | 0.0031623 | uM | 9 | 625.00 | 320.09 | 826.00 | 843.25 | 0.9795 | 0.9706 |
| BT-20 | Erlotinib | 0.01 | uM | 9 | 625.00 | 320.09 | 1079.00 | 843.25 | 1.2796 | 1.3858 |
| BT-20 | Linsitinib | 0.01 | uM | 9 | 625.00 | 320.09 | 956.00 | 843.25 | 1.1337 | 1.1879 |
| BT-20 | 17-AAG | 0.0001 | uM | 9 | 625.00 | 320.09 | 1075.00 | 843.25 | 1.2748 | 1.3795 |
| BT-20 | 17-AAG | 0.01 | uM | 9 | 625.00 | 320.09 | 419.00 | 843.25 | 0.4969 | 0.2125 |
| BT-20 | Linsitinib | 10 | uM | 9 | 625.00 | 320.09 | 645.00 | 843.25 | 0.7649 | 0.6510 |
| BT-20 | 0 | uM | 9 | 625.00 | 320.09 | 1089.00 | 843.25 | 1.2914 | 1.4017 | |
| BT-20 | Lapatinib | 1 | uM | 9 | 625.00 | 320.09 | 948.00 | 843.25 | 1.1242 | 1.1748 |
| BT-20 | Lapatinib | 10 | uM | 9 | 625.00 | 320.09 | 325.00 | 843.25 | 0.3854 | 0.0110 |
| BT-20 | Lapatinib | 0.0033113 | uM | 9 | 625.00 | 320.09 | 972.00 | 843.25 | 1.1527 | 1.2141 |
| BT-20 | Linsitinib | 0.1 | uM | 9 | 625.00 | 320.09 | 828.00 | 843.25 | 0.9819 | 0.9741 |
| BT-20 | Lapatinib | 0.031623 | uM | 9 | 625.00 | 320.09 | 888.00 | 843.25 | 1.0531 | 1.0754 |
| BT-20 | 17-AAG | 0.031623 | uM | 9 | 625.00 | 320.09 | 269.00 | 843.25 | 0.3190 | -0.1170 |
| BT-20 | 0 | uM | 9 | 625.00 | 320.09 | 656.00 | 843.25 | 0.7779 | 0.6711 | |
| BT-20 | 0 | uM | 9 | 1250.00 | 684.27 | 1469.00 | 1739.25 | 0.8446 | 0.7642 | |
| BT-20 | 0 | uM | 9 | 1250.00 | 684.27 | 1532.00 | 1739.25 | 0.8808 | 0.8201 | |
| BT-20 | Erlotinib | 0.0033113 | uM | 9 | 1250.00 | 684.27 | 1843.00 | 1739.25 | 1.0597 | 1.0880 |